Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Nov 10, 2022 12:55am
97 Views
Post# 35087390

RE:RE:RE:RE:RE:RE:RE:RE:Share price will not move up

RE:RE:RE:RE:RE:RE:RE:RE:Share price will not move upI'm super frustrated.  Driving shareholder value is a primary responsibility of the executive team.  We've had a 40% decline so far this year.  I don't care what they think they're waiting on, they have to address it directly with the market.  If they don't know how to do that, they should call WINO or SPCEO1.

SPCEO1 wrote: As best I could tell, my efforts with the weekly report card to influence management in 2021, during a raging bubble, to join the party. Perhaps someone else would have more success but we are in a bear market now, so the benefit of a change in approach now would likely be less impactful. Still, it couldn't hurt to take a different approach as the current approach isn't working and management must be starting to fear a bit for their job security. This close to getting cancer results that will define the future of the company, however, I wouldn't expect much to change. Maybe after those results things will change but not likely before.
Biobob wrote: Anyone care to bring back the weekly rating of our management actions. How do you rate inaction, invisibility, unaccountability.... 




<< Previous
Bullboard Posts
Next >>